What common toxicity is associated with Nivolumab administration?

What common toxicity is associated with Nivolumab administration?

• A. Nausea
• B. Eye irritation
• C. Colitis
• D. Diarrhea

Answer: (C)

Nivolumab is a monoclonal antibody used in immunotherapy for various cancers, and its administration is associated with certain immune-related adverse effects. Colitis is one of the common toxicities linked to Nivolumab treatment. This occurs because Nivolumab works by blocking the programmed cell death protein 1 (PD-1) pathway, which can lead to an inappropriate immune response against the body's own tissues, including the gastrointestinal tract. In cases of colitis, patients typically experience inflammation of the colon, which might present as abdominal pain, cramping, and changes in bowel habits. Monitoring for these symptoms is crucial during treatment, as they can indicate the development of immune-related side effects. The other options—nausea, eye irritation, and diarrhea—while they may occur in some patients, are not as specifically tied to the mechanism of action of Nivolumab as colitis is. For instance, diarrhea could be a symptom of colitis, but colitis itself is more directly associated with Nivolumab's impact on the immune system.

Nivolumab is a monoclonal antibody used in immunotherapy for various cancers, and its administration is associated with certain immune-related adverse effects. Colitis is one of the common toxicities linked to Nivolumab treatment. This occurs because Nivolumab works by blocking the programmed cell death protein 1 (PD-1) pathway, which can lead to an inappropriate immune response against the body's own tissues, including the gastrointestinal tract.

In cases of colitis, patients typically experience inflammation of the colon, which might present as abdominal pain, cramping, and changes in bowel habits. Monitoring for these symptoms is crucial during treatment, as they can indicate the development of immune-related side effects.

The other options—nausea, eye irritation, and diarrhea—while they may occur in some patients, are not as specifically tied to the mechanism of action of Nivolumab as colitis is. For instance, diarrhea could be a symptom of colitis, but colitis itself is more directly associated with Nivolumab's impact on the immune system.